AI assistant
CANN GROUP LIMITED — Investor Presentation 2021
Mar 29, 2021
64603_rns_2021-03-29_20691852-9272-41be-92e9-3c600c7e656c.pdf
Investor Presentation
Open in viewerOpens in your device viewer
==> picture [128 x 50] intentionally omitted <==
==> picture [182 x 53] intentionally omitted <==
ASX ANNOUNCEMENT
30 March 2021
Emyria and Cann Group investor webinar
30 March 2021 - Emyria Limited (ASX: EMD) and Cann Group Limited (ASX: CAN) are pleased to invite shareholders to an Investor Briefing to be held on Thursday 1 April at 11:00 am AEDT
Emyria’s Managing Director, Dr. Michael Winlo, and Cann Group’s COO, Shane Duncan, will discuss the recently announced collaboration agreement to seek accelerated registration of a unique, lowdose, CBD-only capsule with Australia’s Therapeutic Goods Administration (TGA).
Details of the event are as follows:
Event: Emyria and Cann Group Investor Webinar
Webinar Presenters: Emyria’s Managing Director, Dr. Michael Winlo and Cann Group’s COO, Shane Duncan
Date and Time: Thursday 1 April 2021, 11:00am AEDT
Where : Zoom Webinar - details to be provided upon registration
To register your interest in the webinar please click through to the link below.
Registration Link:
- https://janemorganmanagement au.zoom.us/webinar/register/WN_Oh8kr_YWT0W3m0R12NzJew
After registering your interest, you will receive a confirmation email with information about joining the webinar. Participants will be able to submit questions via the panel throughout the presentation, however, we encourage shareholders and investors to send through questions via email beforehand to Lexi O’Halloran at: [email protected]
This announcement has been approved and authorised for release by the Managing Director of Emyria Limited and the Company Secretary of Cann Group Limited.
Cann Group Limited ACN 603 949 739 4 Research Avenue, Bundoora, VIC 3083 Australia Ph: +61 3 9095 7088
==> picture [84 x 33] intentionally omitted <==
==> picture [99 x 30] intentionally omitted <==
For all enquiries to Emyria please contact:
Dr. Michael Winlo Lexi O’Halloran Managing Director Media/Investor Relations (08) 6559 2800 + 61 (0) 404 577 076 [email protected] [email protected]
Andrew Williams Media Relations +61 (0) 412 614 125 [email protected]
For all media enquiries to Cann please contact:
Matthew Wright NWR Communications +61 451 896 420 [email protected]
For all other information regarding Cann Group please contact:
Peter Crock Clive Fanning CEO Head of Investor Relations Cann Group Limited Cann Group Limited +61 3 9095 7088 +61 3 9095 7088 [email protected] [email protected]
About Emyria (www.emyria.com)
Emyria Limited is a data-backed, drug development company. Emyria’s Treatments target unmet needs and are focused on obtaining approval from major global regulators. Emyria’s drug development programs are informed by insights generated from extensive analysis of Emyria Data - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria’s independent clinical services.
(Emerald Clinics - www.emeraldclinics.com.au).
Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs.
About Cann Group
Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved overseas export markets. Cann also owns Satipharm, a Europe-based business exclusively licensed to manufacture, develop and market the proprietary Gelpell delivery system for cannabinoids. Cann has established research and cultivation facilities in Melbourne and is developing a state-of-the-art cultivation and manufacturing facility near Mildura, Victoria. Cann Group has established a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. The Company is commercialising a range of imported and locally sourced and manufactured medicinal cannabis products.
Learn more at: www.canngrouplimited.com | www.satipharm.com
2